Skip to main content
. 2015 Feb 24;5:8569. doi: 10.1038/srep08569

Figure 5. Multiple implantations of fibrin matrices functionalized with FNIII 9-10 + FNIII 11-EDA reduces B16-F10 melanoma tumor growth rate and modulates anti-tumor immune suppression.

Figure 5

C57BL/6J mice were injected s.c. with 2.5 × 105 B16–F10 cells on the back on day 0. On day 3, mice were treated weekly (dashed lines) for three weeks with fibrin gels functionalized with various formulations implanted s.c. Animal were sacrificed either when the tumor reached 200 mm3 or for humane reasons. Individual growth curves (a) and survival curves (b) show that tumor growth was significantly delayed in animals treated with fibrin matrices functionalized with FNIII 11-EDA + FNIII 9-10 (each with an N-terminal TG domain) + TG-TRP-2173–188, comprising the MHC-I immunodominant peptide epitope from the melanocyte-specific protein TRP-2 (TRP-2180–188). (c) The percentage of monocytic myeloid-derived suppressor cells (MO-MDSC, flow-cytometry gated as being CD11b+CD11c-MHC-II-Ly6ChiLy6G-) in the spleen was significantly reduced in the mice treated with the fibrin gel containing and FNIII 9-10 + FNIII 11-EDA (each with an N-terminal TG domain) + TG-TRP-2173–188 compared to the naïve control. Graphs show Kaplan-Meier survival-curves (n = 6–12). Box plots represent median ± 95% confidence interval (n = 3–5). *P < 0.05; **P < 0.01.